473
Views
2
CrossRef citations to date
0
Altmetric
Case Reports

Refractory orthostatic hypotension in a patient with a spinal cord injury: Treatment with droxidopa

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, & show all

References

  • Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni I, et al. Consensus statement on the definition of orthostatic hypotension, neutrally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 2011;21(2):69–72. doi: 10.1007/s10286-011-0119-5
  • Wecht JM, Weir JP, Goldstein DS, Krothe-Petroff A, Spungen AM, Holmes C, et al. Direct and reflexive effects of nitric oxide synthase inhibition on blood pressure. Am J Physiol Heart Circ Physiol 2008;294:190–7. doi: 10.1152/ajpheart.00366.2007
  • Krassioukov A, Claydon VE. The clinical problems in cardiovascular control following spinal cord injury: An overview. Prog Brain Res 2006;152:223–9. doi: 10.1016/S0079-6123(05)52014-4
  • Mathias CJ, Mallipeddi R, Bleasdale-Barr K. Symptoms associated with orthostatic hypotension in pure autonomic failure and multiple system atrophy. J Neurol 1999;246(10):893–898. doi: 10.1007/s004150050479
  • Muneta S, Iwata T, Hiwada K, Murakami E, Sato Y, Imamura Y. Effects of L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in a patient with spinal cord injury. Jap Circ J 1992;56:243–7. doi: 10.1253/jcj.56.243
  • Wecht JM, Rosado-Rivera D, Weir JP, Ivan A, Yenm C, Bauman WA. Hemodynamic Effects os l- Threo-3,4- Dihydroxyphnylserine (Droxidopa) in hypotensive individuals with spinal cord injury. Arch Phys Med Rehabil 2013; 94(10):2006–12. doi: 10.1016/j.apmr.2013.03.028
  • FDA. Drugs @ FDA. Northera approval history. www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed April 5, 2015.
  • Nieshoff EC, Birk TJ, Birk CA, Hinderer SR, Yavuzer G. Double-blinded, placebo-controlled trial of midodrine for exercise performance enhancement in tetraplegia: a pilot study. J Spinal Cord Med 2004;27(3):219–25. doi: 10.1080/10790268.2004.11753752
  • Wecht JM, Rosado-Rivera D, Handrakis JP, Radulovic M, Bauman WA. Effects of midodrine hydrochloride on blood pressure and cerebral blood flow during orthostasis in persons with chronic tetraplegia. Arch Phys Med Rehabil 2010;91(9):1429–35. doi: 10.1016/j.apmr.2010.06.017
  • Barber DB, Rogers SJ, Fredrickson MD, Able AC. Midodrine hydrochloride and the treatment of orthostatic hypotension in tetraplegia: two cases and a review of the literature. Spinal Cord 2000;38(2):109–11. doi: 10.1038/sj.sc.3100959
  • Groomes TE, Huang CT. Orthostatic hypotension after spinal cord injury: treatment with fludrocortisone and ergotamine. Arch Phys Med Rehabil 1991;72(1):56–8.
  • Frisbie JH, Steele DJ. Postural hypotension and abnormalities of salt and water metabolism in myelopathy patients. Spinal Cord 1997;35(5):303–7. doi: 10.1038/sj.sc.3100436
  • Northera [package insert]. Deerfield, IL: Lundbeck NA Ltd; 2014.
  • Kaufmann H. L-Dihydroxyphenylserine (droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience. Clin Auton Res 2008;18:19–24 doi: 10.1007/s10286-007-1002-2
  • Kaufmann H, Saadia D, Voustianiouk A, Goldstein DS, Holmes C, Yahr MD, et al. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation 2003;108:724–8. doi: 10.1161/01.CIR.0000083721.49847.D7
  • Mathias CJ. L-Dihydroxyphenylserine (droxidopa) in the treatment of orthostatic hypotension: the European experience. Clin Auton Res 2008;18:25–9. doi: 10.1007/s10286-007-1005-z
  • Kauffmann H, Norcliffe-Kauffmann L, Palma JA. Droxidopa in neurogenic orthostatic hypotension. Expert Rev Cardiovasc Ther 2015;13(8):875–91. doi: 10.1586/14779072.2015.1057504
  • Getting your patient started with Northera (droxidopa). Deerfield, IL: Lundbeck NA Ltd; 2015. https://northera.com/pdf/northera-treatment-form.pdf. Accessed April 5, 2015.
  • Biaggioni I, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H, et al. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension 2015;65(1):101–7. doi: 10.1161/HYPERTENSIONAHA.114.04035
  • Kaufmann H, Freeman, Biaggioni I, Low P, Pedder S, Hewitt LA, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology 2014;83(4):328–35. doi: 10.1212/WNL.0000000000000615

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.